Featured Research

from universities, journals, and other organizations

Study links real-time data to flu vaccine strategies

Date:
December 29, 2009
Source:
Arizona State University
Summary:
Adaptive vaccination strategies, based on age patterns of hospitalizations and deaths monitored in real-time during the early stages of a pandemic, outperform seasonal influenza vaccination allocation strategies, according to a new article.

Adaptive vaccination strategies, based on age patterns of hospitalizations and deaths monitored in real-time during the early stages of a pandemic, outperform seasonal influenza vaccination allocation strategies, according to findings reported Dec. 3 by researchers, including two from Arizona State University, in the online journal PLoS ONE.

Using data from the A(H1N1) influenza outbreak in Mexico earlier this year, the authors conclude that a modeling approach that targets specific age groups for vaccinations, could help countries develop policies to mitigate the impact of ongoing and secondary pandemic waves.

"These new data shed light on which age groups are at high risk of infection and transmission during a pandemic influenza outbreak. Unlike seasonal vaccination strategies that target young children and seniors, our adaptive strategy based on early epidemiological data prioritized the young and adults between the ages of 20 and 59 years, which was based on the pattern of hospitalizations and deaths during the Mexican pandemic outbreak," says mathematical epidemiologist Gerardo Chowell-Puente, an assistant professor in the School of Human Evolution and Social Change in ASU's College of Liberal Arts and Sciences.

The adaptive vaccination strategy relied on data reported to the Mexican National Epidemiological Surveillance System on hospitalization and deaths 25 and 37 days into the outbreak. The study's adaptive strategy yielded a 37 percent reduction in hospitalizations and 42 percent reduction in deaths if the vaccinations started on day 25 of the outbreak and reached 20 percent of the population. The benefits of the strategy were slightly lower on day 37 of the outbreak, providing a 35 percent reduction in influenza-related deaths and 22 percent reduction in hospitalizations when compared to seasonal influenza that targets traditional high-risk age groups (infants, young children and persons 65 years and older).

"The adaptive strategy was found to be effective in reducing the number of hospitalizations and deaths during a pandemic influenza when vaccine resources are scarce," says Chowell-Puente. "Knowledge of age-specific rates is crucial in helping policymakers develop intervention policies that could help to save lives. If vaccine supplies are limited, targeting these age groups should be considered."

Chowell-Puente is co-author of the study "Adaptive vaccination strategies to mitigate pandemic influenza: Mexico as a case study," which appears in PLoS One, the online journal published by the Public Library of Science. Other authors include Xiaohong Wang with ASU's Mathematical and Computational Modeling Sciences Center; Cιcile Viboud and Mark A. Miller with the Fogarty International Center, National Institutes of Health; and Stefano Bertozzi with Mexico's National Institute of Public Health and the University of California, Berkeley.

Chowell-Puente also is co-author of a study of the A(H1N1) influenza pandemic strain, which reported an age shift in the proportion of cases toward a younger population when compared with historical patterns of seasonal influenza in Mexico. Those findings were published June 29 online in the New England Journal of Medicine.


Story Source:

The above story is based on materials provided by Arizona State University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Chowell et al. Adaptive Vaccination Strategies to Mitigate Pandemic Influenza: Mexico as a Case Study. PLoS ONE, 2009; 4 (12): e8164 DOI: 10.1371/journal.pone.0008164

Cite This Page:

Arizona State University. "Study links real-time data to flu vaccine strategies." ScienceDaily. ScienceDaily, 29 December 2009. <www.sciencedaily.com/releases/2009/12/091203163144.htm>.
Arizona State University. (2009, December 29). Study links real-time data to flu vaccine strategies. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/12/091203163144.htm
Arizona State University. "Study links real-time data to flu vaccine strategies." ScienceDaily. www.sciencedaily.com/releases/2009/12/091203163144.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins